28th week of 2017 patent applcation highlights part 8 |
Patent application number | Title | Published |
20170196861 | METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE - Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (C | 2017-07-13 |
20170196862 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention features a compound of formula I: | 2017-07-13 |
20170196863 | MODIFIED MICROBUBBLE AND METHOD OF MAKING THE SAME - A modified microbubble is provided. The modified microbubble includes an albumin microbubble and a plurality of chitosan oligosaccharide lactates. The albumin microbubble includes an albumin shell and a gas core inside the albumin shell. The plurality of chitosan oligosaccharide lactates is connected to an outer surface of the albumin shell. | 2017-07-13 |
20170196864 | Azetidine Derivatives - Compounds of formula (I) are inhibitors of fatty acid amide hydrolase, (FAAH), and which are useful in the treatment of diseases or medical conditions which benefit from inhibition of FAAH activity, such as anxiety, depression pain, inflammation, and eating, sleep, neurodegenerative and movement disorders: | 2017-07-13 |
20170196865 | TREATMENT OF AUTOIMMUNE DISEASE - Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors. | 2017-07-13 |
20170196866 | INTERMITTENT DOSING OF MDM2 INHIBITOR - The present disclosure relates to mdm2 inhibitors for use in specific dosing schedules. It was found that if sufficiently potent or, in alternative, sufficiently high dose of a Mdm2 inhibitor is used, it can cause antineoplastic effect by triggering much longer lasting antiproliferative mechanism in cells. The long lasting effect can sustain for several weeks after a single dose, which eliminates the need for daily treatment and allows administering the Mdm2 | 2017-07-13 |
20170196867 | INHIBITORS OF BETA-SECRETASE - The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates. | 2017-07-13 |
20170196868 | METHODS AND COMPOSITIONS FOR TREATMENT OF HER-POSITIVE CANCERS - Cancers that overexpress tyrosine kinase receptors of HER family are treated with drugs acting on these receptors. Although HER-targeting drugs have revolutionized the treatment of HER-positive cancers, high rates of primary and treatment-emergent resistance limit their clinical utility. The present inventors have now discovered that combining HER-targeting drugs with a selective inhibitor of CDK8/19 greatly improves the efficacy of such drugs, offering an improved approach to the treatment of HER-positive cancers. | 2017-07-13 |
20170196869 | Methods for treating Her2-positive breast cancer - Methods of treating breast cancer are provided where a quantitative Her2 assay is used to identify whether a breast tumor will be responsive to treatment with anti-Her2 therapeutic agents such as lapatinib and trastuzumab, followed by selection of a suitable treatment regimen and administration of the regimen. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in breast tumor cells collected from breast tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the breast cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein. | 2017-07-13 |
20170196870 | PHARMACEUTICAL COMPOSITION FOR TREATING ULCERATIVE COLITIS - Provided is a pharmaceutical composition for treating ulcerative colitis, comprising a compound represented by a formula (1) or a pharmaceutically acceptable salt thereof, wherein the compound or the pharmaceutically acceptable salt is administered in an amount of 600 mg or more per day to an ulcerative colitis patient. | 2017-07-13 |
20170196871 | Therapeutic and Diagnostic Method for Ataxia-Telangiectasia - ATM kinase is shown to regulate proteasome-mediated protein turnover through suppression of the expression of the ubiquitin-like protein ISG15 (Interferon Stimulated Gene 15). Silencing of the ISG15 pathway restored both the ubiquitin and autophagy pathways, and the UV-mediated degradation of their substrates in A-T cells. The ATM kinase negatively regulates the ISG15 pathway, and the constitutively elevated ISG15 pathway induces proteinopathy in A-T cells, and in A-T patients. These findings indicate that proteasome-mediated protein degradation is impaired in A-T cells due to elevated expression of the ISG15 conjugation pathway, which contributes to progressive neurodegeneration in A-T patients. The ISG15 pathway is a new target for both detection and treatment of A-T. Inhibitors if ISG15 expression can be used to inhibit or attenuate neurodegeneration in A-T patients. In addition, an inhibitor of the early phase of autophagy, 3-MA, was shown to be effective in decreasing the impaired proteasome-mediated protein degradation in A-T cells, and thus would be effective in decreasing the neurodegeneration in A-T patients. | 2017-07-13 |
20170196872 | METHODS OF TREATING PATIENTS SUFFERING FROM MOVEMENT DISORDERS - The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A | 2017-07-13 |
20170196873 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS - A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions. | 2017-07-13 |
20170196874 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE - The invention relates to compounds and methods for modulating one or more components of a kinase cascade. | 2017-07-13 |
20170196875 | THERAPEUTIC NANOPARTICLES FOR THE TREATMENT OF NEUROBLASTOMA AND OTHER CANCERS - A therapeutic nanoparticle comprising: at least one oncologic drug; and taurolidine, whereby to provide the simultaneous delivery of the at least one oncologic drug and taurolidine, thereby harnessing the synergistic effect of taurolidine on the at least one oncologic drug. | 2017-07-13 |
20170196876 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS - New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed. | 2017-07-13 |
20170196877 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE - An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug. | 2017-07-13 |
20170196878 | USE OF CBP/EP300 AND BET INHIBITORS FOR TREATMENT OF CANCER - The present invention relates to the use of CBP/EP300 inhibitors and BET inhibitors for the treatment of cancer. In some embodiments, the use is to treat cancer that is resistant to BET inhibitors. | 2017-07-13 |
20170196879 | Use of Inhibitor of Apoptosis Protein (IAP) Antagonists in HIV Therapy - Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (1APs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist. | 2017-07-13 |
20170196880 | ANTITUMOR ACTIVITY OF MULTI-KINASE INHIBITORS IN TRIPLE NEGATIVE BREAST CANCER - A composition comprising
| 2017-07-13 |
20170196881 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. | 2017-07-13 |
20170196882 | COBALT PORPHYRINS FOR THE TREATMENT OF BLOOD-RELATED DISORDERS - The use of cobalt porphyrins for the manufacture of an agent for mobilizing bone marrow cells to peripheral blood, preferably used to treat congenital neutropenia, for the treatment and prevention of neutropenia caused by chemotherapy, radiotherapy and pharmacologically-induced neutropenia, for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndromes, and to increase the amount of circulating hematopoietic stem cells in peripheral blood for subsequent isolation in the process of apheresis and allogeneic or autologous transplantation. | 2017-07-13 |
20170196883 | DERIVATIVES OF 7-FLUORO-8-CHLORO-5H-DIBENZO [B,E,] [1,4] DIAZEPINE AND USE THEREOF - This present disclosure generally relates to medicine, and in particular to pharmacology and psychiatry, and discloses active agents and related methods of treatment which can be used for the treatment of treatment-resistant forms of schizophrenia. In some exemplary aspects, such treatments allow for eliminating both the positive and negative symptoms of schizophrenia, and cognitive disorders, without causing severe side effects that limit their use, such as sedation, tachycardia, orthostatism, agranulocytosis and sialorrhea. | 2017-07-13 |
20170196884 | ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS - The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions. | 2017-07-13 |
20170196885 | USE OF GABAA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS | 2017-07-13 |
20170196886 | USE OF ESTETROL AS EMERGENCY CONTRACEPTIVE - The present invention relates to a new use of tetrahydroxylated estrogens such as estetrol (1,3,5(10)-estratrien-3, 15α, 16α, 17β-tetrol), namely in a method of emergency contraception. The method of emergency contraception according to the invention comprises the oral administration of estetrol in a single dose within 120 hours of sexual intercourse. | 2017-07-13 |
20170196887 | COMPOSITIONS COMPRISING EXEMESTANE AND NOVEL METHODS OF USE - In addition to its potent mechanism-dependent inhibition of estrogen biosynthesis, in accordance with the embodiments of the present invention, it has now been found that exemestane has novel chemoprotective properties which have hitherto not been explicitly recognized. The present invention provides methods for the use of compositions comprising exemestane for chemoprotection against a wide variety of non-mammary tumors (and possibly other chronic diseases) that are not estrogen-dependent, but have oxidative stress, inflammation and electrophile-damaging etiologies. The present invention also shows that exemestane shows powerful synergism with other classes of Nrf2-activators and phase 2 enzyme gene activators, including, for example sulforaphane (an isothiocyanate), shikonin (a naphthoquinone), zerumbone (a cyclic sesquiterpene) and resveratrol (a stilbene derivative), which increases the attractiveness of exemestane's novel uses. | 2017-07-13 |
20170196888 | COMPOSITIONS AND METHODS FOR TREATING CANCER - A method of treating cancer in a subject in need thereof is provided. The method comprising administering to the subject a receptor tyrosine kinase (RTK)-specific cancer therapy and a glucocorticoid or a glucocorticoid analog, such that an efficacy window of said RTK-specific cancer therapy and an efficacy window of said glucocorticoid or glucocorticoid analog substantially overlap. | 2017-07-13 |
20170196889 | Betamethasone Oral Spray Formulation and Method of Use to Treat Ataxia - A stable oral spray formulation comprising a glucocorticoid together with other excipients is disclosed. In preferred embodiments, the spray formulation is used to treat neurological disorders such as ataxia by being sprayed in an effective dose into the mouth of a patient. | 2017-07-13 |
20170196890 | TGR5 AGONIST COMPLEXES FOR TREATING DIABETES AND CANCER - Provided herein are complexes of metformin or metformin analogues and a TGR5 ligand that are useful in treating diseases including diabetes, cardiovascular disease, and cancer. | 2017-07-13 |
20170196891 | FATTY ACID BILE ACID CONJUGATES FOR TREATMENT OF LIPODYSTROPHY - Provided are methods of treating and/or reducing risk of lipodystrophy using compositions including at least one fatty-acid/bile-acid conjugate (FABAC). Further provided are methods of treating HIV-associated lipodystrophy using said FABACs. | 2017-07-13 |
20170196892 | COMPOSITIONS AND METHODS FOR THE REPAIR OF MYELIN - Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder. | 2017-07-13 |
20170196893 | TREATMENT OF INFLAMMATORY DEMYELINATING DISEASE WITH AGONISTS OF FARNESOID X RECEPTOR - Provided herein are methods and compositions for treating demyelinating inflammatory diseases by administering to the subject an effective dose on an FXR agonist. | 2017-07-13 |
20170196894 | Pharmaceutical Composition Comprising 7 Beta -Hydroxycholesterol Intravenous Administration - The present invention relates to a pharmaceutical composition comprising (a) 7β-hydroxycholesterol, (b) a water soluble organic solvent, preferably propylene glycol and/or DMSO, and (c) a solubilizing agent, preferably PEG hydrated castor oil, and to a method for preparing the same. This composition is suitable for preparing an intravenously administered preparation and comprises the pharmaceutically active substance β-hydroxycholesterol, which is poorly soluble in water. | 2017-07-13 |
20170196895 | COMPOSITION COMPRISING GPCR19 AGONIST AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING ALLERGIC DERMATITIS - The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate(HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis. The said pharmaceutical composition also reduces infiltration of a mast cell, eosinophil, and neutrophil in dermis and ameliorates clinical symptoms such as erythema, hemorrhage, edema, excoriation, erosion, scaling and dryness. Thus, the said pharmaceutical composition can be used to prevent and treat allergic skin diseases. | 2017-07-13 |
20170196896 | GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY TO MAXIMIZE DRUG CONCENTRATIONS IN THE STRATUM CORNEUM AND SERUM AND METHODS OF USE THEREOF - Disclosed herein are gel compositions for enhanced transdermal delivery of an active ingredient into a serum of a subject through production of a reservoir of the active ingredient in the stratum corneum of the subject. Also disclosed herein are methods of using the gel composition to at least partially ameliorate a condition, and kits comprising the gel composition. | 2017-07-13 |
20170196897 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE EPIDERMAL DISEASES - The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration that include a vitamin D metabolite, calcipotriol, and nicotinamide in a combination that is particularly effective in treating and in the maintenance therapy of psoriasis and other related dermal disorders and diseases. | 2017-07-13 |
20170196898 | MEDICAMENT - Suggested is a medicament which is particularly useful for preventing, curing or abating of cough and inflammations of the respiratory system, comprising or consisting of active pharmaceutical ingredients and 1,3-propandiol. | 2017-07-13 |
20170196899 | STABLE PHARMACEUTICAL COMPOSITIONS - The present invention relates to a stable pharmaceutical composition comprising tigecycline and arginine, to a process for the manufacture of said pharmaceutical composition as well as to its use in the treatment of bacterial infections. | 2017-07-13 |
20170196900 | SYSTEMS FOR TREATING PULMONARY INFECTIONS - Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a | 2017-07-13 |
20170196901 | COMBINATION DRUG THERAPIES FOR CANCER AND METHODS OF MAKING AND USING THEM - In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices for treating, preventing or ameliorating a tumor or a cancer, and methods for treating, preventing or ameliorating a tumor or a cancer. In alternative embodiments, provided are therapeutic combinations, pharmaceutical compositions, formulations, kits and devices comprising: a beta adrenergic receptor antagonist (a “beta blocker”) such as propranolol; a non-steroidal anti-inflammatory drug (a NSAID) such as etodolac; a gemcitabine or GEMZAR™; and, a taxane, a paclitaxel, TAXOL™, ONXOL™, an albumin-bound paclitaxel (nab-paclitaxel) or ABRAXANE™, or any equivalent thereof. In alternative embodiments, the therapeutic combinations further comprise an anti-cancer or anti-tumor antibody, a cytokine, and/or a chemotherapeutic agent. | 2017-07-13 |
20170196902 | ANTITUMOR USE OF CYCLIC DINUCLEOTIDE CGMP - The present invention belongs to the field of medicine technology, particularly relating to an application of cyclic dinucleotide (cGAMP) in tumor treatment. Researches carried out in the present invention show that, cGAMP can inhibit growth of many types of tumor cells, with remarkable anti-tumor effect, thus, it can be used in preparation of anti-tumor drugs; and the prepared anti-tumor drugs have low toxicity and favorable effect. Proved by a subcutaneous tumor model in nude mice, cGAMP has a remarkable inhibition effect on tumors of human gastric carcinoma cell line MNK-45, human lung adenocarcinoma cell line A549, human colorectal carcinoma cell line Lovo, human hepatocellular carcinoma cell line SMMC-7721, human prostatic carcinoma cell line PC-3 and human pancreatic carcinoma cell SW1990, which are subcutaneously implanted in nude mice, and also proved by animal acute toxicity experiment. cGAMP has a relatively low acute toxicity, therefore and may be used for preparing anti-tumor drugs. | 2017-07-13 |
20170196903 | COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA - The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance. | 2017-07-13 |
20170196904 | SILICONE OIL-CONTAINING FORMULATIONS FOR NASAL APPLICATION - Silicone oil-containing formulation for nasal application for use in a method for intranasal treatment of endogenous diseases of the nose and/or those due to exogenous causes, e.g. those which are caused by bacteria, fungi, viruses and/or allergens, wherein the silicone oil or the formulation is optionally enriched with oxygen, preferably in the presence of emulsifiers, and optionally in the presence of further active ingredients, such as α-sympathomimetic drugs, e.g. oxymetazoline or xylometazoline, and related subjects of the invention. | 2017-07-13 |
20170196905 | NITRIC OXIDE RELEASING NAIL COATING COMPOSITIONS, NITRIC OXIDE RELEASING NAIL COATINGS, AND METHODS OF USING THE SAME - The present invention relates to nitric oxide (NO)-releasing nail coating compositions, NO-releasing coatings, and methods of using the same, for example, to treat fungal infections of a nail. It is noted that aspects described with respect to one embodiment may be incorporated in different embodiments although not specifically described relative thereto. Provided according to embodiments of the invention are nitric oxide (NO)-releasing nail coating compositions and/or coatings. | 2017-07-13 |
20170196906 | NOBLE GAS TREATMENT OF ALZHEIMER'S DISEASE AND TAUPATHIES - The invention discloses means of utilizing Noble Gases for inhibition of pathogenic processes associated with Alzheimer's Disease progression, as well as reversal of Alzheimer's Disease. In one embodiment compositions containing xenon gas are administered alone or together with therapeutic interventions for treatment of Alzheimer's Disease. In another embodiment, taupathies such as chronic traumatic encephalopathy are treated by administration of xenon or Noble Gas containing mixtures. | 2017-07-13 |
20170196907 | DIALYSIS FORMULATION - A replacement fluid for dialysis treatment includes selenium in a concentration of 0.6-1.8 μM, and rubidium in a concentration of 1.4-4.2 μM. The replacement fluid is essentially free of one or more of the trace elements selected from chromium, manganese, and copper. | 2017-07-13 |
20170196908 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY - A method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by GPCR signaling pathways. | 2017-07-13 |
20170196909 | ANTIINFECTIVE FREE INTRAMAMMARY VETERINARY COMPOSITION - An antiinfective-free formulation for prophylactic treatment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminium stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages. | 2017-07-13 |
20170196910 | GAMMA DELTA T CELLS AND USES THEREOF - A method of preparing and using gamma delta T cells in the allogeneic or autologous treatment of subjects suffering from virus infection, fungal infection, protozoal infection and cancer. | 2017-07-13 |
20170196911 | REDUCING CXCR4 EXPRESSION AND/OR FUNCTION TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS - Provided herein are methods of enhancing engraftment of hematopoietic stem cells (HSC) in recipient subjects by reducing expression (or activity) of CXC chemokine receptor 4 (CXCR4). Such methods can be used in gene therapy protocols and in HSC transplantation, for example allowing this to occur without radiation or chemotherapy conditioning as is typically done in non-myeloablative HSC transplant. In some examples, gene editing methods are used to delete one copy of the CXCR4 gene before HSC or bone marrow transplantation, enhancing the efficiency and durability of donor cell repopulation. | 2017-07-13 |
20170196912 | METHODS OF PREPARING AND USING NOVEL STEM CELL COMPOSITIONS AND KITS COMPRISING THE SAME - The present invention provides novel stem cell compositions having significant therapeutic and practical advantages, as well as methods of preparing and using such compositions for the treatment and prevention of injury and disease in patients. The invention may be applied to stem cell populations isolated from a wide variety of animals, including humans, and tissues. In particular applications, the invention is used to prepare a stem cell composition from a collagen-based tissue, such as adipose tissue, isolated from a patient, and the stem cell composition is subsequently provided to a site of actual or potential injury in the patient. The invention further includes related kits comprising the stem cell compositions, which are remarkably stable and retain viability and efficacy during storage and shipment. | 2017-07-13 |
20170196913 | ENHANCEMENT OF GLUCOSE-STIMULATED INSULIN SECRETION BY CELLS THROUGH INDUCTION OF CELLULAR SENESCENCE - Methods for increasing glucose induced insulin secretion in an insulin secreting cell by inducing senescence in the cell are provided. Further, methods for treating diabetes, by providing cells with increased glucose induced insulin secretion to a subject, as well as a population of modified insulin secreting cells are provided. | 2017-07-13 |
20170196914 | COMPOSITIONS AND METHODS - Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health. | 2017-07-13 |
20170196915 | DIETARY SUPPLEMENTS CONTAINING PROBIOTICS - Dietary supplements comprising at least one probiotic and at least one of animal digest, dried brewers yeast, vitamin C; vitamin E, beta carotene, zinc proteinate, manganese proteinate, ferrous sulfate, copper proteinate, calcium iodate, and sodium selenite. The probiotics and other ingredients are present in the supplement in amounts sufficient to enhance the palatability of the probiotics and compositions containing the probiotics, enhance the immune system to augment the beneficial effects of the probiotics, or extend the life of the probiotics. | 2017-07-13 |
20170196916 | BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS FOR USE IN DECREASING ABDOMINAL PAIN IN A POSTMENOPAUSAL WOMAN - The present invention is based upon the findings of two large clinical studies to determine the efficacy of daily consumption of the probiotic strain | 2017-07-13 |
20170196917 | AGENT FOR PREVENTION AND TREATMENT OF CHLAMYDIA INFECTION - An agent for the prevention and treatment of | 2017-07-13 |
20170196918 | New Strain Of Lactobacillus Casei With Ability To Degrade The Immunotoxic Peptide From Gluten - The invention relates to a bacterial strain, | 2017-07-13 |
20170196919 | ANTI-BACTERIAL LYSATE OF PROBIOTIC BACTERIA - The invention relates to probiotic bacteria and particularly, although not exclusively, to anti-bacterial compositions derived from probiotic bacteria. Disclosed are compositions comprising material secreted from probiotic bacteria, uses thereof, and methods using the compositions. Particularly contemplated are compositions comprising material secreted from | 2017-07-13 |
20170196920 | Compositions and Related Methods For Treating Hyperadrenocorticism - A composition for treating hyperadrenocorticism includes a therapeutically effective amount of a pharmaceutical dosage form including melatonin, lignan, phosphatidylserine, and at least one probiotic organism-containing material. The composition may be used to treat canine Cushing's disease, for example. | 2017-07-13 |
20170196921 | MICROBIAL COMPOSITIONS FOR IMPROVING MILK PRODUCTION IN RUMINANTS - The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome. | 2017-07-13 |
20170196922 | METHODS FOR IMPROVING MILK PRODUCTION BY ADMINISTRATION OF MICROBIAL CONSORTIA - The disclosure relates to isolated microorganisms—including novel strains of the microorganisms—microbial consortia, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial consortia, and compositions comprising the same, in methods for modulating the production and yield of milk and milk components in ruminants. In particular aspects, the disclosure provides methods of increasing desirable components of milk in ruminants. Furthermore, the disclosure provides for methods of modulating the rumen microbiome. | 2017-07-13 |
20170196923 | Cannabis-Hemp Paste - The present invention provides a commercial process for preparing the ‘ | 2017-07-13 |
20170196924 | COMPOSITION FOR SUPPORTING CELLULAR STRUCTURE AND ADHESION - The present invention is a composition comprising: (a) protein selected from the group consisting of soy protein and pea protein; (b) sunflower seed protein; (c) turmeric; and (d) bitter melon. The composition is useful as a dietary supplement, a food, a complementary medicine or a therapeutic agent. Furthermore, the composition may be prepared in any form including, for example, powder, emulsion, liquid, capsule, pill and food items such as nutrition bars. | 2017-07-13 |
20170196925 | AQUEOUS FORMULATION COMPRISING A LIPOPHILIC COMPOSITION - An aqueous formulation comprising between 0.1% and 50% by weight of lipophilic composition, said formulation further comprising between 0.1% and 10% by weight of homogenising component comprising at least microcrystalline cellulose; between 0.01% and 2% by weight of clay; and the remainder in water. | 2017-07-13 |
20170196926 | USES OF CISTANCHE TUBULOSA EXTRACT AND ISOACTEOSIDE IN PROTECTING MUSCLE | 2017-07-13 |
20170196927 | COMPOSITION FOR ARTHRITIS, MOBILITY AND DELAY AGEING - The present invention relates to a composition comprising green tea extract, collagen and chondroitin. Such a composition can be used for use in treating or preventing arthritis, for increasing life expectancy in an animal, for preventing signs of aging, for use in preserving mobility or preventing decline in mobility in an animal and in a method for making such compositions. The composition can be also used in a method of treating arthritis, a method of increasing life expectancy, a method of preserving mobility or preventing decline in mobility or a method of delaying aging. | 2017-07-13 |
20170196928 | OCULAR EYELID SCRUB COMPOSITION FOR THE TREATMENT OF DEMODEX BLEPHARITIS - A composition for the treatment of | 2017-07-13 |
20170196929 | PHYTO-ACTIVE BASED ANTI-CANCER FORMULATION - The present disclosure relates to a formulation for preventing and treating cancer which avoids the undesirable side effects observed when using the conventional therapies. The formulation in accordance with the present disclosure comprises a formulation having active constituents comprising a combination of extracts from | 2017-07-13 |
20170196930 | PROCESS FOR MANUFACTURING GLATIRAMER ACETATE PRODUCT - The patent provides a process of preparing a pharmaceutical preparation of glatiramer acetate and mannitol in a suitable container comprising the steps of:
| 2017-07-13 |
20170196931 | Methods of Administering Vasopressors - The present disclosure relates to the use of angiotensinogen, angiotensin I, angiotensin I, angiotensin III, and/or angiotensin IV in therapeutic methods for the treatment of hypotension, such as catecholamine-resistant hypotension. | 2017-07-13 |
20170196932 | PHARMACEUTICAL COMPOSITION CONTAINING LEUPROLIDE AND HAVING BOTH IMMEDIATE AND SUSTAINED RELEASE PROPERTIES - The present invention relates to a pharmaceutical composition containing leuprolide acetate and having both immediate and sustained release properties and, more specifically, to a pharmaceutical composition in which, on the basis of the total weight of active ingredients, leuprolide as an immediate release preparation is contained in 0.001 wt % to 25 wt %; and leuprolide contained in microspheres of a sustained release preparation is contained in 75 wt % to 99.999 wt %. The pharmaceutical composition of the present invention is characterized by satisfying both a drug immediate release property so as to realize the prompt exposure to a sufficient amount of drug at the early stage for expression of medicinal effects and a drug sustained release property for four weeks or longer, and the pharmaceutical composition is effective in the prevention and treatment of sex hormone-dependent positive or malignant diseases. | 2017-07-13 |
20170196933 | THERAPEUTIC COMPOSITIONS INCLUDING FRATAXIN, LACTOFERRIN, AND MITOCHONDRIAL ENERGY GENERATING ENZYMES, AND USES THEREOF - Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH | 2017-07-13 |
20170196934 | ORAL PHARMACEUTICAL COMPOSITION - An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximise absorption and/or therapeutic efficiency. | 2017-07-13 |
20170196935 | RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOF - A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction. | 2017-07-13 |
20170196936 | ORNITHODOROS MOUBATA COMPLEMENT INHIBITOR FOR USE IN THE TREATMENT OF COMPLEMENT-MEDIATED DISEASES IN PATIENTS WITH C5 POLYMORPHISM - The present invention relates to methods of treating or preventing a complement-mediated disease and/or disorder in a subject with a complement C5 polymorphism, including administering to a subject in need thereof a therapeutically or prophylactically effective amount of an agent that a) inhibits the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibits eicosanoid activity. The invention also relates to methods of identifying patient populations with C5 polymorphisms that are treatable with specific agents that a) inhibit the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibit eicosanoid activity. | 2017-07-13 |
20170196937 | COMPOSITIONS COMPRISING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn's disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen. | 2017-07-13 |
20170196938 | CARRIER-FREE BIOLOGICALLY-ACTIVE PROTEIN NANOSTRUCTURES - The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell. | 2017-07-13 |
20170196939 | FORMULATIONS OF DILUTED AMINO ACID SEGMENTS AND METHODS FOR MAKING SAME - A formulation of a diluted amino acid fragment is prepared by mixing an amino acid fragment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid fragment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation. | 2017-07-13 |
20170196940 | OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME - Provided are oxyntomodulin analogs. The peptide analogs have at least two cysteines. The two cysteines are separated by six amino acids such that they can be crosslinked using suitable crosslinking moieties. The crosslinked peptides have long half-lives and/or efficacy. For example, peptide analog compositions are used for inducing weight loss and/or reducing blood glucose levels. | 2017-07-13 |
20170196941 | HIGH-PURITY INHALABLE PARTICLES OF INSULIN AND INSULIN ANALOGUES, AND HIGH-EFFICIENCY METHODS OF MANUFACTURING THE SAME - A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 μm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more. | 2017-07-13 |
20170196942 | HIGH-PURITY INHALABLE PARTICLES OF INSULIN AND INSULIN ANALOGUES, AND HIGH-EFFICIENCY METHODS OF MANUFACTURING THE SAME - A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 μm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more. | 2017-07-13 |
20170196943 | COMPOSITION FOR TREATING DIABETES MELLITUS COMPRISING INSULIN AND A GLP-1/ GLUCAGON DUAL AGONIST - A composition for preventing or treating diabetes mellitus includes insulin and a GLP-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker. A method for preventing or treat diabetes mellitus includes administration of the insulin and a GLP-1/glucagon dual agonist. | 2017-07-13 |
20170196944 | METHOD TO REDUCE MUSCLE ATROPHY FOLLOWING ORTHOPEDIC SURGERY - A method for reducing muscle atrophy in an individual undergoing orthopedic surgery, the method comprising administering to said individual a mixture of protein and non-protein nutrients for 4-7 days pre-surgery and for 10-21 days post-surgery. The protein dosage is 15-30 g, of which 17-25% is leucine, 23-35% is 1-glutamine, 10-15% is 1-arginine and 1-2% is cysteine. The protein nutrients are derived from a combination of commercially available proteins and the appropriate free amino acid. The non-protein nutrients are a mono or disaccharide in the amount of 15-30%, N-acetyl-cysteine in the amount of 1-15% and the antioxidant Vitamin C. | 2017-07-13 |
20170196945 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS - Embodiments of the technology described herein are based upon the discoveries that neutrophil extracellular traps (NETs) provide a stimulus for thrombus formation and that NETs are present in stored blood products. Accordingly, some embodiments relate to methods of treating and preventing toxicity of NETs and thrombosis caused by NETs. Additional embodiments are directed towards methods of treating stored blood products to prevent transfusion-related injuries. | 2017-07-13 |
20170196946 | BOTULINUM TOXIN AND COLLOIDAL SILVER PARTICLES - Botulinum toxin is combined with colloidal silver particles to provide improved compositions for use in medical and cosmetic treatments. | 2017-07-13 |
20170196947 | PEPTIDE AND A USE THEREOF - The disclosure relates to a peptide (SEQ ID NO: 5), the use of said peptide for the treatment of the symptoms associated with pain, the use of said peptide for the inhibition of the activity of influenza virus and a pharmaceutical composition containing the peptide. | 2017-07-13 |
20170196948 | Methods, Antibodies, and Vaccines Utilizing Epitopes of Alpha Synuclein for Treatment of Parkinsons Disease - The present invention pertains to a dendritic cell-based vaccine against rh-α-Syn, α-synuclein specific peptide antibodies and related vaccines, and methods of treating, preventing, and/or vaccinating against Parkinson's Disease (PD), or symptoms thereof. | 2017-07-13 |
20170196949 | NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY - The present invention relates to a method for prevention and/or treatment of an autoimmune disease, comprising administering a composition, said composition comprising at least one beta cell autoantigen, to a subject The subject may have a serum vitamin-D level above 50 nanomole/liter or the composition may be administered by intralymphatic injection or injection directly into a lymph node, or over a period of weeks, months, or years. The invention also relates to a composition comprising a plurality of particles, each having immobilised on its surface at least one first and at least one second antigen, wherein the first antigen is a beta cell autoantigen, and the second antigen is either a tolerogen or a beta cell autoantigen, and to composition comprising i) at least one beta cell autoantigen, and at least one of iia) an IL-10 inducing compound selected from the group consisting of vitamin-D, vitamin-D analogs, tyrosine kinase inhibitors, gamma-amino butyric acid, and gamma-amino butyric acid analogs; and iib) a compound that reduces the dendritic cells' ability to activate naïve CD4+ Tcells, such as a cyclooxygenase inhibitor, a CTLA-4 compound or a TNF alpha inhibitor. The invention also relates to pharmaceutical kits and to medical use of beta cell autoantigens. | 2017-07-13 |
20170196950 | METHOD FOR PRODUCING AUTOLOGOUS TOLEROGENIC DENDRITIC CELLS (TOLDCS) WITH SPECIFIC ANTIGENS AND THEIR USE IN THE PREPARATION OF A MEDICAMENT USEFUL FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - The invention relates to a method for producing tolerogenic dendritic cells (tolDCs) with specific antigens, comprising the steps of: (a) culturing precursors of dendritic cells in an animal-serum-free medium, using cytokines, IL-4 and GM-CSF, in order to differentiate same in dendritic cells; (b) producing apoptotic cells; (c) culturing the dendritic cells obtained in step (b) in the presence of compounds having anti-inflammatory activity; (d) co-culturing the dendritic cells from step (d) with the apoptotic cells from step (c), such as to stimulate the endocytosis of the apoptotic cells by the dendritic cells; (e) and, by means of identification based on phenotypic evaluation, determining the production of tolerogenic dendritic cells (tolDCs) with specific antigens. The invention also relates to the tolDC cells produced with said method and to the use of said tolDCs with specific antigens in the production of a drug suitable for the treatment of systemic lupus erythematosus. | 2017-07-13 |
20170196951 | POLYVALENT ANTI-TUMOR FIBROBLAST VACCINE - Compositions of matter, of production, and treatment modalities are disclosed for the prevention and/or therapeutic reduction of tumors through induction of immunity against tumor associated fibroblasts and components of tumor microenvironment. In one embodiment of the invention, placentally derived fibroblast cells are cultured under conditions replicating tumor microenvironment. Expression of CD248 on said cultured fibroblasts is used as a marker of effective manipulation. Cells expressing CD248 are utilized a immunogens for stimulation of immunity towards cancer associated fibroblastic cells. | 2017-07-13 |
20170196952 | VACCINES AGAINST AN ONCOGENIC ISOFORM OF ESR1 AND METHODS OF USING THE SAME - Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering the cancer therapeutic or prevention agent and a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding an ESR1 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the ESR1 polypeptide to treat a cancer or precancer are also provided. | 2017-07-13 |
20170196953 | VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME - Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent. | 2017-07-13 |
20170196954 | PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR - Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial. | 2017-07-13 |
20170196955 | METHOD FOR PREPARING DENDRITIC CELL, DENDRITIC CELL PREPARED THEREBY, AND USE THEREOF - The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same. | 2017-07-13 |
20170196956 | KIF20A Epitope Peptides for TH1 Cells and Vaccines Containing the Same - Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors. | 2017-07-13 |
20170196957 | RECOMBINANT T CELL RECEPTOR LIGAND COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CANCER - Disclosed herein are compositions and methods for treating or inhibiting prostate cancer. The compositions include a MHC molecule including covalently linked first and second domains, wherein the first domain is an MHC class II β1 domain and the second domain is an MHC class II α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain, and a prostate specific antigen peptide covalently linked to the first domain. The methods include administering a disclosed MHC molecule to a subject with prostate cancer. | 2017-07-13 |
20170196958 | GLYCOCONJUGATE VACCINES - The disclosure relates to a glycoconjugate vaccine conferring protection against | 2017-07-13 |
20170196959 | ANTI-MYCOPLASMA SPP. SUBUNIT VACCINE - Provided in the present invention are anti- | 2017-07-13 |
20170196960 | NOVEL METHOD AND COMPOSITIONS - The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants. | 2017-07-13 |